Browsing by Author "Provencio, Mariano"

Sort by: Order: Results:

  • Rueda, Antonio; García-Sanz, Ramón; Pastor, Miguel; Salar Silvestre, Antonio; Labrador, Jorge; Quero-Blanco, Cristina; Casanova, María; Provencio, Mariano; Gotel and Geltamo (Informa Healthcare , 2015)
    BACKGROUND: Relapsed or refractory (R/R) classical Hodgkin lymphoma (cHL) after autologous stem cell transplantation (ASCT) remains a challenge. For these patients treatments with different mechanisms of action rather ...
  • Herrera, Mercedes; Herrera, Alberto; Domínguez, Gemma; Silva, Javier; García, Vanesa; García, Jose M.; Gómez, Irene; Soldevilla, Beatriz; Muñoz, Concepción; Provencio, Mariano; Campos Martin, Yolanda; García de Herreros, Antonio; Casal, José Ignacio; Bonilla, Félix; Peña, Cristina (Japanese Cancer Association, 2013)
    Tumor epithelial cells within a tumor coexist with a complex microenvironment in which a variety of interactions between its various components determine the behavior of the primary tumors. Cancer-associated fibroblasts ...
  • Martínez-Martínez, Esther; Gómez, Irene; Martín, Paloma; Sánchez, Antonio J.; Román, Laura; Tejerina, Eva; Bonilla, Félix; García Merino, Antonio; García de Herreros, Antonio; Provencio, Mariano; García, Jose M. (Impact Journals, 2015)
    Many studies have demonstrated that the endocannabinoid system (ECS) is altered in different tumor types, including colon cancer. However, little is known about the role of the ECS in tumor progression. Here we report the ...
  • Arriola Aperribay, Edurne; García Gómez, Ramón; Diz Tain, Pilar; Majem, Margarita; Martínez Aguillo, Maite; Valdivia, Javier; Paredes, Alfredo; Sánchez-Torres, José Miguel; Peralta Muñoz, Sergio; Barneto, Isidoro; Gutierrez, Vanesa; Andrade Santiago, Jesús Manuel; Aparisi, Francisco; Isla, Dolores; Ponce, Santiago; Vicente Baz, David; Artal, Angel; Amador, Mariluz; Provencio, Mariano (BioMed Central, 2018)
    BACKGROUND: Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is ...
  • Berghoff, Anna S.; Bellosillo Paricio, Beatriz; Caux, Christophe; de Langen, Adrianus; Mazieres, Julien; Normanno, Nicola; Preusser, Matthias; Provencio, Mariano; Rojo, Federico; Wolf, Jurgen; Zielinski, Christoph C. (BMJ Publishing Group, 2019)
    The introduction of targeted treatments and more recently immune checkpoint inhibitors (ICI) to the treatment of metastatic non-small cell lung cancer (NSCLC) has dramatically changed the prognosis of selected patients. ...
  • Majem, Margarita; Hernández Hernández, Juan Ramón; Hernando-Trancho, F.; Rodríguez de Dios, Núria; Sotoca, A.; Trujillo-Reyes, Juan Carlos; Vollmer, Ivan; Delgado-Bolton, R.; Provencio, Mariano (Springer, 2020)
    Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable tumours. To improve the prognostic capacity of the TNM classification, ...
  • Sánchez-Herrero, Estela; Serna-Blasco, Roberto; Ivanchuk, Vadym; García-Campelo, Rosario; Dómine Gómez, Manuel; Sánchez, José M.; Massutí, Bartomeu; Reguart, Noemí; Camps, Carlos; Sanz-Moreno, Sandra; Calabuig-Fariñas, Sílvia; Jantus-Lewintre, Eloisa; Arnal, Magdalena; Fernández-Orth, Dietmar; Calvo, Virginia; González-Rumayor, Víctor; Provencio, Mariano; Romero, Atocha (Wiley, 2021)
    Despite impressive and durable responses, nonsmall cell lung cancer (NSCLC) patients treated with anaplastic lymphoma kinase (ALK) inhibitors (ALK-Is) ultimately progress due to development of resistance. Here, we have ...

Search DSpace

Browse

My Account

In collaboration with Compliant to Partaking